Apremilast + Placebo

Phase 2UNKNOWN

0 views this week 0 watching💤 Quiet

Interest: 31/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lichen Planus of Vulva

Conditions

Lichen Planus of Vulva, Female Genital Disease

Trial Timeline

Sep 24, 2019 → Dec 31, 2023

NCT ID

NCT03656666

About Apremilast + Placebo

Apremilast + Placebo is a phase 2 stage product being developed by Amgen for Lichen Planus of Vulva. The current trial status is unknown. This product is registered under clinical trial identifier NCT03656666. Target conditions include Lichen Planus of Vulva, Female Genital Disease.

What happened to similar drugs?

0 of 2 similar drugs in Lichen Planus of Vulva were approved

Approved (0) Terminated (0) Active (2)

🔄Dupilumab + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06122649	Phase 3	Completed	Nov 27, 2023	Dec 5, 2025	Plaque Psoriasis
NCT04804553	Phase 3	Recruiting	Mar 17, 2022	Dec 29, 2028	Active Juvenile Psoriatic Arthritis
NCT05174065	Phase 3	Completed	Mar 8, 2022	Jun 1, 2024	Palmoplantar Pustulosis
NCT04528082	Phase 3	Recruiting	Sep 9, 2021	Dec 17, 2030	Behçet Disease
NCT04057937	Phase 2	Completed	Oct 16, 2019	Jun 7, 2021	Palmoplantaris Pustulosis
NCT03656666	Phase 2	UNKNOWN	Sep 24, 2019	Dec 31, 2023	Lichen Planus of Vulva
NCT03774875	Approved	Completed	Mar 28, 2019	Nov 3, 2021	Psoriasis
NCT02802735	Phase 1	Completed	Jun 22, 2016	Aug 5, 2016	Pharmacokinetics
NCT02289417	Phase 2	Completed	Jan 8, 2015	Jun 3, 2019	Ulcerative Colitis
NCT02307513	Phase 3	Completed	Dec 30, 2014	Jul 17, 2020	Behçet's Syndrome
NCT01232283	Phase 3	Completed	Nov 22, 2010	Nov 30, 2016	Plaque Psoriasis
NCT00456092	Phase 2	Completed	Mar 5, 2007	May 9, 2009	Psoriatic Arthritis

Competing Products

12 competing products in Lichen Planus of Vulva

See all competitors

Product	Company	Stage	Hype Score
LP-10 (Liposomal Tacrolimus)	Lipella Pharmaceuticals	Phase 2	29
Tacrolimus cream + Clobetasol cream	Astellas Pharma	Phase 2	35
Baricitinib 4 milligram Oral Tablet	Eli Lilly	Phase 2	39
pimecrolimus and clobetasol + clobetasol 0.05% cream	Novartis	Phase 2	35
Pimecrolimus 1% cream	Novartis	Phase 2	35
secukinumab 300 mg Q4W + secukinumab 300 mg Q2W	Novartis	Phase 2	35
Deucravacitinib	Bristol Myers Squibb	Phase 2	35
Dupilumab + Placebo	Sanofi	Phase 3	44
Dupilumab + Placebo	Sanofi	Phase 3	44
Amevive (Alefacept) + Placebo	Biogen	Phase 2	24
Ruxolitinib cream + Vehicle cream	Incyte	Phase 2	32
Ruxolitinib cream + Vehicle cream	Incyte	Phase 2	32